Phase II trial evaluating Gleevec (imatinib mesylate formerly known as STI571) in patients with anaplastic thyroid cancer.
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Imatinib (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- 23 Mar 2011 Planned end date changed from 1 Apr 2005 to 1 Aug 2010 as reported by ClinicalTrials.gov
- 23 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 19 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.